International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic)

Takahiro Soda, Declan M. McLoughlin, Scott R. Clark, Leif Oltedal, Ute Kessler, Jan Haavik, Chad Bousman, Daniel J. Smith, Miquel Bioque, Caitlin C. Clements, Colleen Loo, Fidel Vila-Rodriguez, Alessandra Minelli, Brian J. Mickey, Roumen Milev, Anna R. Docherty, Julie Langan Martin, Eric D. Achtyes, Volker Arolt, Ronny RedlichUdo Dannlowski, Narcis Cardoner, Emily Clare, Nick Craddock, Arianna Di Florio, Monika Dmitrzak-Weglarz, Liz Forty, Katherine Gordon-Smith, Mustafa Husain, Wendy M. Ingram, Lisa Jones, Ian Jones, Mario Juruena, George Kirov, Mikael Landén, Daniel J. Müller, Axel Nordensköld, Erik Pålsson, Meethu Paul, Agnieszka Permoda, Bartlomiej Pliszka, Jamie Rea, Klaus O. Schubert, Joshua A. Sonnen, Virginia Soria, Will Stageman, Akihiro Takamiya, Mikel Urretavizacaya, Stuart Watson, Maxim Zavorotny, Allan H. Young, Eduard Vieta, Janusz K. Rybakowski, Massimo Gennarelli, Peter P. Zandi, Patrick F. Sullivan, Bernhard T. Baune

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Recent genome-wide association studies have demonstrated that the genetic burden associated with depression correlates with depression severity. Therefore, conducting genetic studies of patients at the most severe end of the depressive disorder spectrum, those with treatment-resistant depression and who are prescribed electroconvulsive therapy (ECT), could lead to a better understanding of the genetic underpinnings of depression. Despite ECT being one of the most effective forms of treatment for severe depressive disorders, it is usually placed at the end of treatment algorithms of current guidelines. This is perhaps because ECT has controlled risk and logistical demands including use of general anaesthesia and muscle relaxants and side-effects such as short-term memory impairment. Better understanding of the genetics and biology of ECT response and of cognitive side-effects could lead to more personalized treatment decisions. To enhance the understanding of the genomics of severe depression and ECT response, researchers and ECT providers from around the world and from various depression or ECT networks, but not limited to, such as the Psychiatric Genomics Consortium, the Clinical Alliance and Research in ECT, and the National Network of Depression Centers have formed the Genetics of ECT International Consortium (Gen-ECT-ic). Gen-ECT-ic will organize the largest clinical and genetic collection to date to study the genomics of severe depressive disorders and response to ECT, aiming for 30,000 patients worldwide using a GWAS approach. At this stage it will be the largest genomic study on treatment response in depression. Retrospective data abstraction and prospective data collection will be facilitated by a uniform data collection approach that is flexible and will incorporate data from many clinical practices. Gen-ECT-ic invites all ECT providers and researchers to join its efforts.

Original languageEnglish (US)
Pages (from-to)921-932
Number of pages12
JournalEuropean Archives of Psychiatry and Clinical Neuroscience
Issue number7
StatePublished - Oct 1 2020


  • Bipolar disorder
  • Cognition
  • ECT
  • Electroconvulsive therapy
  • GWAS
  • Genomic
  • Major depressive disorder
  • Severe depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)


Dive into the research topics of 'International Consortium on the Genetics of Electroconvulsive Therapy and Severe Depressive Disorders (Gen-ECT-ic)'. Together they form a unique fingerprint.

Cite this